Eledon Pharmaceuticals, Inc. (ELDN) Q3 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and welcome to the Elladon Pharmaceuticals third quarter 2022 financial results conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to Paul Little, Chief Financial Officer of Elladon. Mr. Little, please go ahead. Good afternoon, everyone, and thank you for joining Elladon's third quarter 2022 operating and financial results conference call. Today, I am joined by David Alexander Groh, Chief Executive Officer, Steve Perrin, our President and Chief Scientific Officer, and Jeff Borenstein, our Chief Medical Officer. Earlier today, Elladon issued a press release announcing financial results for the third quarter ended September 30, 2022. You may access the release under the Investors tab on our company's website at eladon.com. I would like to remind everyone that statements made during this conference call relating to Eladon's expected future performance, future business prospects, or future events or plans may include forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are intended to be subject to the safe harbor protection provided by the Reform Act. Actual outcomes and results could differ materially from these forecasts, due to the impact of many factors beyond the control of Elladon. Elladon expressly disclaims any duty to provide updates to its forward-looking statements, whether as a result of new information, future events, or otherwise. Participants are directed to the risk factors set forth in...